KONFERENCE OG TEMADAG I KØBENHAVN 30 November 2017 RESPONSIBLE PHARMA 2017 1 Thomas Alslev Christensen Head of Operations WHO WE ARE It began with insulin in 1922 Our history is important in order to understand our values ID: 798810
Download The PPT/PDF document "CSR and Responsible Research and Innov..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
CSR and Responsible Research and Innovation in the Novo Nordisk Foundation Group
KONFERENCE OG TEMADAG I KØBENHAVN
30. November 2017
RESPONSIBLE PHARMA 2017
1
Thomas Alslev Christensen
Head of Operations
Slide2WHO WE ARE
Slide3It
began
with insulin in 1922
Our history is important in order to understand our values:
THE SCIENTISTS
Marie Krogh and August Krogh
THE INVESTOR
August Kongsted
THE CLINICIAN
H.C. Hagedorn
THE ENTREPRENEUR
Thorvald Pedersen
THE ENTREPRENEUR
Harald Pedersen
Slide4Corporate objective
to
provide a stable basis for the commercial and research activities of the Novo Group companies
(
and of companies in which the Novo A/S may hold a material equity interest or over which it may have material influence)
4
Grant-giving objectives
to support physiological, endocrinological, metabolic and other medical research,
to support Danish research hospital activities within diabetes,
to support other scientific, humanitarian and social purposes
Our objectives
Slide5An independent foundation with corporate interests
5
Investments
Grants
Scientific
research
Diabetes treatment
Innovation
Education & outreach
Humanitarian
and social
causes
Principal investments
Venture investments
Seed investments
Financial investments
25.5% SHARES
70.9% VOTES
27.5% SHARES
75% VOTES
Dividends
100% SHARES
25.5% SHARES
25.5% VOTES
Dividends
Investment
result
in 2016:
DKK 8.4 billion
(EUR 1.1 billion)
Grants
awarded
in 2016
:
DKK 4.2 billion
(EUR 565 million)
Slide6HOW WE WORK WITH CSRIN THE NOVO NORDISK FOUNDATION GROUP
EACH COMPANY HAS RESPONSIBILITIES TO PEOPLE AND PLANET
WE REPORT OVERALL IMPACT:
* RESEARCH & INNOVATION * COMMERCIAL ACTIVITIES * ENVIRONMENTAL & CLIMATE
* SOCIAL AND HEALTH * WORK ENVIRONMENT & EMPLOYMENT
* ECONOMY
3
Slide7GUIDING PRINCIPLES &
OVERALL CSR POLICIES OF THE
NOVO NORDISK FOUNDATION
GROUP
7
Slide8Charter for the Novo Group
Decided by the Novo Nordisk
Foundation’s Board of Directors
The Foundation’s ownership
role is exercised by:
The
companies must meet the criteria of the charter:Improve peoples live and workInnovator
Best in businessValue-based management
Open and honestImprove environment, social and financial performance
International conventions
Slide9IMPLEMENTATION:UN GLOBAL COMPACT
Novo Nordisk A/S and
NovoZymes A/S
Responsible business by supporting the UN GLOBAL COMPACT and being UNGC LEAD members
The Ten Principles
are derived from:
* the Universal Declaration of Human Rights, * the International Labour
Organization’s Declaration on Fundamental Principles and Rights at Work, * the Rio Declaration on Environment and Development
, * the
United Nations Convention Against Corruption
.
Slide10SUSTAINABILITY
Novo Nordisk A/S and NovoZymes A/S
23/10/2017
NOVO NORDISK A/S:
The Triple Bottom Line (TBL) is a key element of the company’s
values-based management system
formalised in the Novo Nordisk Way. It is how business is done. NOVOZYMES A/S:
Integrating sustainability into the core of our business, making it a key component of business strategies and management processes
Slide11SUSTAINABILITYNovo Nordisk Foundation
Values and cornerstones
23 October 2017
11
Laws and
regulations
Labour practicesWorking environment
Environment
Standards for
good
research
practice
for grant
recepients
Slide12CREATING SUSTAINABLE
VALUE IN SOCIETY
Supports research,
education
, innovation, research hospital and social and
humanitarian
causes
Scientific
discoveries
Innovation
New
companies
New
developments
New
knowledge
Research-
based
education
Highly
qualified
workforce
Existing
companies
Patient
treatments
Health,
education
, and social
well-being
for vulnerable
individuals
and
groups
Slide13Novo Nordisk Foundation Strategy 2014-2018
13
Societal goal: With Denmark as the Foundation’s
centre
of gravity the prime focus is:
To
promote world-class research and innovation in the medical, biotechnological and natural sciences and help to foster a world-class education system.To help to develop a knowledge-based society that contributes to long-term economic activity and job creation for improving general health and welfare.
SOCIETAL
GOAL
GRANT GIVING
GOALS
THE FOUNDATION’S
STRATEGY
COMMERCIAL GOALS
Grant-giving goals
Strengthen
biomedical and biotechnology research in selected fields.
Fuel cross-
disciplinarity
.
Advance individual scientific excellence.
Spur imagination, inspiration and knowledge about science and technology.
Build bridges between scientific discoveries and their commercial applications.
Achieve social and humanitarian impact.
Commercial goals:
Be
a strong owner of the companies in the Novo Group.
Generate attractive investment returns for the Foundation on its financial investment portfolio.
Make investments with the main goal of promoting knowledge and world-class research.
Slide141.1
billion
Applications
received
Awarded
~DKK
Grants
awarded
Success
rate
for research
applications
WHAT DO WE DO
4.2
billion
Paid
out ~DKK
1811
~
18
%
326
2016
Slide15Research and innovation
grants
Laureate
Research Grant
Young
Investigator
AwardHallas Møller InvestigatorExcellence ProjectBorregaard Clinical
Sciencist
Prizes
Innovation
Project
Grants
Challenge
Programme
Interdisciplinary
Synergy
Programme
Humanitarian
& Social
Slide16Five large research
centres
DKK 4 billion invested
10 year center grant duration
Over 800 staff in total
300 researchers recruited
abroadCopenhagen Bioscience Conference series
Increase the visibility of research and innovation in the region
Recruit outstanding scientists and talent
Stimulate cross-pollination between academia, hospitals and industry
Contribute to a knowledge based
society
Metabolic
Research
Stemcell
Research
Protein
Research
Biobank
Biosustainability
Slide1707 November 2017
-will
raise the level of care for everyone with diabetes in Denmark through:
Evidence-based treatment through Denmark’s five administrative regions
Nationwide collaboration on research, health promotion and education
Access to everyone with diabetes in Denmark with opportunities for large cohort studies
Steno Diabetes Centres
17
Slide18Nobel Lectures
Museum of Natural History
Copenhagen International School
The Danish Diabetes Academy
Highschool
Teaching Prize &
Science Teacher Prize
Virtual
Laboratory
Young Investigators
BioPro
World
Talent Campus
LIFE
EDUCATION AND OUTREACH
Slide1907 November 2017
Grants
for
humanitarian and social purposes
19
Slide20Awarded to humanitarian and social not-for-profit organizations
(in 2016)
DKK >3.8 million
Glacier flour
– improving
tropical soil
(in 2016)
DKK 5 million
Unicef
‘No Lost Generation’
DKK 1.6 million
Humanitarian/social grants (expected)
Selected projects from 2016 and 2017
Social
Humanitarian
2%
of
the grant
budget 2017
:
DKK
66 million
Teach First
Danmark
DKK 7.5 million
Global Young Citizens
DKK 2 million
Children’s development and welfare
DKK 6 million
WWF:
Discover Nature
DKK 1 million
Project ASFALT
(pilot study)
DKK 9.4 million
Diabetes complications
in Greenland
DKK 2.5 million
Slide21Humanitarian/social grants (expected)
Selected projects from 2018 and 2019
Social
Humanitarian
8
%
of
the grant
budget 2018:
DKK
400 million
Slide22The
Novo Nordisk Foundation Group
Annual Review
Adheres to the International Financial Reporting Standards just as the companies in the Novo Group and is sent to
Erhvervsstyrelsen
jf. Årsregnskabslovens § 99 a.
Reporting on activity, impact and CSR
Facts &
Results
An
extended
management
report
.
The Novo Nordisk Foundation Group and Danish Society
”CSR
report
”.
Impact
Assessment
Report
An annual report on the effects of the Foundation’s grants.
Creating
Knowledge,
Improving
Health
A printed as well as online magazine
about the Foundation’s
activities.
Communication
of
impact
and results sciencenews.dk FacebookLinkedin Youtube
Slide23Thank you for your
attention!
KONFERENCE OG TEMADAG I KØBENHAVN
30. November 2017RESPONSIBLE PHARMA 2017
23